2 Small Cap AI Stocks for Your Watch List
(5:15) - Top Picks To Keep On Your Watchlist Right Now
(41:35) - Episode Roundup: AATC, DUOT
Podcast@Zacks.com
Welcome to Episode #445 of the Zacks Market Edge Podcast.
Every week, host and Zacks stock strategist, Tracey Ryniec, will be joined by guests to discuss the hottest investing topics in stocks, bonds, and ETFs and how it impacts your life.
This week, Tracey is joined by Zacks Small Cap Analyst, Mark Zinski, to talk about 2 small cap companies that are involved in the AI Revolution.
Unlike the last time Mark was on the podcast, this week's stocks are not in the health care sector but are in technology services.
The large cap companies aren't the only way to play AI. There will be opportunities for many small companies as well. But investors will have to do their research to find them.
Tracey and Mark are here to share 2 stocks this week.
2 Small Cap AI Stocks for Your Watch List
1. Autoscope Technologies Corp. (AATC)
Autoscope Technologies is a global company that has AI-enabled platforms like IntelliSight which provides data analytics on traffic. It's 'smart traffic.' Autoscope Technologies has a market cap of $41 million.
Autoscope Technologies has royalty income and has a gross margin of 95% and low capex.
Autoscope Technologies is a rare small cap company that pays a dividend. In 2024 it paid a special dividend in addition to the regular dividend. Autoscope's regular dividend is currently yielding 8%.
Be aware, Autoscope is thinly traded on the over-the-counter market.
Should Autoscope Technologies be on your watch list?
2. Duos Technologies Group, Inc. (DUOT)
Duos Technologies Group has several business segments. One uses AI to analyze fast moving vehicles, including railcars. Another segment, Duos Energy, owns gas turbines. A third segment is its Edge Data Center segment.
Duos Technologies Group has a market cap of $87 million. It is more heavily traded than Autoscope, with about 100,000 shares traded daily.
Duos Technologies does not pay a dividend. But total revenue in 2025 is expected to be up and will fall between $28 and $30 million.
Get More Information on YouTube
Be sure to check the description box on this video on YouTube for links to the Zacks Research Report and Zacks Detailed Estimates.
What Else Should You Know About Small Cap AI Stocks?
Tune into this week's podcast to find out.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Autoscope Technologies Corporation (AATC) : Free Stock Analysis Report
Duos Technologies Group, Inc. (DUOT) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Apple's new ‘Charismatic' smart home OS is getting set to take on Alexa and Google
When you buy through links on our articles, Future and its syndication partners may earn a commission. Bloomberg's Mark Gurman recently wrote an article about Apple working to enter the smart home space with robots and other AI platforms. The news was heavily reported by nearly every publication at the time, including our piece that broke down Apple's smart robot plans. However, few people discussed a key piece of information from Gurman's reporting: Apple is reportedly working on an entirely new operating system for its smart home devices, which it has codenamed "Charismatic." What we know about 'Charismatic' Recent years have seen Apple stick with the same operating systems — iOS, iPadOS, watchOS, tvOS and macOS. It's been a while since Apple has introduced anything new in the operating system space. The company rolling out a new OS for smart home devices is a big deal. Why? Because it shows that Apple is committed to making its smart home hub stand out — it's not just adapting its existing large-screen operating systems, it's allegedly designing something new. Google and Amazon have established strong footholds in the smart home market, and Apple's HomePod devices haven't gained as much traction. If a screen-based hub is introduced in the near future with a brand-new Apple OS, it could draw more attention and allow Apple to establish itself as a major player in the smart home world. How will 'Charismatic' work? It sounds like Apple's new smart home operating system is all about support for multiple users with seamless switching. "The devices are meant to be easily shared: They include a front-facing camera that can scan users' faces as they walk toward it and then automatically change the layout, features and content to the preferences of that person," said Gurman in his report. As far as using Apple's new OS goes, it sounds like Siri will be a significant part of it, much like Alexa and Google Assistant run smart homes alongside other major players in the space. Gurman also mentions a touchscreen component, which is to be expected if the device is meant to serve as a true hub for all connected devices. Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button. More from Tom's Guide I biked 12 miles with the Apple Watch 10 vs Samsung Galaxy Watch 8, and there's a clear winner Apple Watch 11 — all the biggest rumors so far Mark your calendars — iPhone 17 release date may have just leaked
Yahoo
14 hours ago
- Yahoo
Prediction: This Unstoppable Stock Will Join Nvidia, Microsoft, Apple, Amazon, and Alphabet in the $2 Trillion Club by 2028
Key Points The need for next-generation AI processors has skyrocketed in recent years. Taiwan Semiconductor is the foundry trusted by the biggest names in AI and is well-positioned to prosper from these secular tailwinds. While it forms the foundation (or should I say "foundry") of the AI revolution, the stock is attractively priced. 10 stocks we like better than Taiwan Semiconductor Manufacturing › A paradigm shift has been under way in the world of technology over the past few years, driven by advances in the field of artificial intelligence (AI). In fact, the world's five most valuable companies by market cap, worth more than $2 trillion each, are arguably at the forefront of AI innovation. AI chipmaker Nvidia recently became the first company to surpass a $4 trillion market cap, as its graphics processing units (GPUs) are the gold standard for AI workloads, propelling its valuation to $4.5 trillion. Microsoft's growing suite of cloud-based AI tools has fueled its growth spurt, clocking in at $3.9 trillion. Apple has a captive audience of more than 1 billion iPhones amid an Apple Intelligence upgrade, driving its value to $3.4 trillion. Rounding out the top five are cloud and AI leaders Alphabet and Amazon, sporting market caps of $2.5 trillion and $2.4 trillion, respectively, as of this writing. With a current market cap of roughly $1.3 billion, Taiwan Semiconductor Manufacturing (NYSE: TSM), often referred to as TSMC, is, I predict, on the fast track to become a member of the $2 trillion club by 2028. The adoption of AI continues to gain momentum, driving up demand for its most advanced chips in the process. As the world's largest and most renowned semiconductor foundry, TSMC seems ordained to join this elite collection of businesses. A chip off the old block After years of working in the shadows, TMSC has recently found itself in the limelight. The company describes itself as the "world's first dedicated semiconductor foundry," occupying a pivotal position in a tech world that increasingly relies on lightning-fast chips for AI and high-performance computing (HPC). And make no mistake, no chipmaker is held in as high a regard as TSMC. The company includes Nvidia, Arm Holdings (NASDAQ: ARM), Advanced Micro Devices (NASDAQ: AMD), and Apple among its biggest customers. The tech landscape has shifted since the dawn of AI. TSMC once depended on smartphone chips for the lion's share of its revenue, but HPC, including the specialized processors used for AI, has become the company's biggest breadwinner, recently accounting for 60% of sales. TSMC's growth is accelerating. Revenue grew 44% year over year to $30 billion in U.S. dollars (USD) in the second quarter, while earnings per American depositary receipt of $2.47 soared 67%. The company is expecting this surging growth to continue. Management's forecast is calling for third-quarter revenue of $32.4 billion in USD at the midpoint of its guidance, representing growth of about 38%. The path to $2 trillion TSMC sits in an enviable position as the world pivots to AI. Since the biggest names in technology use its industry-leading processors, it stands to benefit from the accelerating adoption of generative AI -- which has spread like wildfire over the past few years. Furthermore, TSMC's accelerating revenue provides evidence that it's well positioned to capitalize on this opportunity and will soon be catapulted into the company of multi-trillionaires. According to Wall Street, TSMC is on track to generate revenue of roughly $122 billion in 2025, giving it a forward price-to-sales (P/S) ratio of about 10.4. Assuming its P/S remains constant, TSM would have to generate revenue of $192 billion annually to support a $2 trillion market cap. Even more intriguing is that Wall Street is forecasting revenue growth of 16% and 19% in 2026 and 2027, respectively -- and TSMC has consistently outpaced expections. If the company clears those low-double-digit hurdles, it would probably achieve a $2 trillion market cap sometime in early 2029. However, given the company's history of outperformance -- and the accelerating opportunity -- I predict it will happen even sooner. Estimates regarding the expanding adoption of AI vary wildly. One of the more conservative estimates posits that generative AI could add between $2.6 trillion and $4.4 trillion to the global economy annually over the next decade, according to global management consulting firm McKinsey & Company. Even the more conservative estimates have been climbing as new use cases for AI are uncovered. Finally, at 28 times trailing-12-month earnings, TSMC is attractively valued, offering an economical way to invest in the once-in-a-generation opportunity afforded by AI. Should you buy stock in Taiwan Semiconductor Manufacturing right now? Before you buy stock in Taiwan Semiconductor Manufacturing, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Taiwan Semiconductor Manufacturing wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Danny Vena has positions in Alphabet, Amazon, Apple, Microsoft, and Nvidia. The Motley Fool has positions in and recommends Advanced Micro Devices, Alphabet, Amazon, Apple, Microsoft, Nvidia, and Taiwan Semiconductor Manufacturing. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Prediction: This Unstoppable Stock Will Join Nvidia, Microsoft, Apple, Amazon, and Alphabet in the $2 Trillion Club by 2028 was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Pediatrix Medical Group Announces $250 Million Share Repurchase Program
FORT LAUDERDALE, Fla., August 18, 2025--(BUSINESS WIRE)--Pediatrix Medical Group, Inc. (NYSE: MD), a leading provider of physician services, today announced that its Board of Directors has authorized a share repurchase program of up to $250 million of the Company's outstanding common stock. "In view of our strong cash flow, current and forecasted cash balances and relatively low debt levels, our Board has authorized a $250 million share repurchase program, which we plan to use opportunistically," said Mark S. Ordan, Chair of the Board and Chief Executive Officer. "We will weigh the use of the repurchase program continually against other potential strategic uses of cash to provide the best long-term return to our shareholders and the strongest future for our business." The timing and actual number of shares repurchased will depend on a variety of factors, including market price of the shares, general business and market conditions, applicable legal requirements, and alternative investment opportunities. The Company intends to execute the repurchase program consistent with its capital allocation strategy of prioritizing investment to grow the business over the long term. Repurchases may be made through privately negotiated transactions or open market transactions, including pursuant to a trading plan in accordance with Rule 10b5-1 and/or Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The repurchase program has a three-year term and may be suspended for periods or discontinued at any time. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by multiple pediatric subspecialties. The group's high-quality, evidence-based care is bolstered by significant investments in research, education, quality-improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through approximately 4,400 affiliated physicians and other clinicians. To learn more about Pediatrix, visit or follow us on Facebook, Instagram, LinkedIn and the Pediatrix blog. Investment information can be found at Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to the Company's objectives, plans, strategies and financial performance, statements regarding the amount, timing and execution of, and sources of funding for, repurchases under the repurchase program, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future . These statements are often characterized by terminology such as "believe," "hope," "may," "anticipate," "should," "intend," "plan," "will," "expect," "estimate," "project," "positioned," "strategy" and similar expressions, and are based on assumptions and assessments made by the Company's management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company's most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled "Risk Factors", as well the Company's current reports on Form 8-K, filed with the Securities and Exchange Commission, and include the impact of the Company's practice portfolio management plans and whether the Company is able to achieve the expected favorable impact to Adjusted EBITDA therefrom; the impact of the Company's termination of its then third-party revenue cycle management provider and transition to a hybrid revenue cycle management model with one or more new third-party service providers, including any transition costs associated therewith; the impact of surprise billing legislation; the effects of economic conditions on the Company's business; the effects of the Affordable Care Act, the One Big Beautiful Bill Act and potential additional healthcare reform; the Company's relationships with government-sponsored or funded healthcare programs, including Medicare and Medicaid, and with managed care organizations and commercial health insurance payors; the Company's ability to comply with the terms of its debt financing arrangements; the impact of management transitions; the timing and contribution of future acquisitions or organic growth initiatives; the effects of share repurchases; and the effects of the Company's transformation initiatives, including its reorientation on, and growth strategy for, its hospital-based and maternal fetal medicine businesses. View source version on Contacts Kasandra H. RossiExecutive Vice President, Chief Financial Officer & Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
